Detection and investigation of invasive mould disease

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL. 1, 2011, Pages

  Cuenca Estrella, Manuel ^a   Bassetti, Matteo ^b   Lass Flörl, Cornelia ^c   Ráčil, Zdeněk ^d   Richardson, Malcolm ^e   Rogers, Thomas R ^f  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF GENOA   (Italy)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^f TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

D glucan; Cultures; Galactomannan; Microscopic examination; PCR based diagnosis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BETA 1,3 GLUCAN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FUNGAL DNA; FUNGUS ANTIGEN; GALACTOMANNAN; ITRACONAZOLE; NUCLEIC ACID; POSACONAZOLE; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BODY FLUID; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CHEMOPROPHYLAXIS; CRYPTOCOCCOSIS; DIAGNOSTIC PROCEDURE; DNA DETERMINATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; EARLY DIAGNOSIS; FUNGAL DETECTION; FUNGUS CULTURE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPROMISED PATIENT; INVASIVE ASPERGILLOSIS; LEUKEMIA; LOWER RESPIRATORY TRACT INFECTION; MICROSCOPY; NOSE INFECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; SYSTEMIC MYCOSIS; ZYGOMYCOSIS;

ANTIGENS, FUNGAL; CLINICAL LABORATORY TECHNIQUES; DNA, FUNGAL; DRUG MONITORING; FUNGI; HUMANS; IMMUNOCOMPROMISED HOST; MICROBIAL SENSITIVITY TESTS; MYCOLOGY; MYCOSES; OPPORTUNISTIC INFECTIONS;

EID: 78650574445     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq438     Document Type: Article

References (97)

1. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 2010; 50: 405-15.
2. Marr KA. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol 2010; 22: 138-42.
3. Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230-40.
4. Einsele H, Loeffler J. Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients. Clin Microbiol Infect 2008; 14 Suppl 4: 37-45.
5. Gadea I, Cuenca-Estrella M, Martin E et al. Microbiological procedures for diagnosing mycoses and for antifungal susceptibility testing. Enferm Infecc Microbiol Clin 2007; 25: 336-40.
6. Lass-Flörl C. Zygomycosis: conventional laboratory diagnosis. Clin Microbiol Infect 2009; 15 Suppl 5: 60-5.
7. Richardson M, Ellis M. Clinical and laboratory diagnosis. Hosp Med 2000; 61: 610-4.
8. Rickerts V, Mousset S, Lambrecht E et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007; 44: 1078-83.
9. Bialek R, Konrad F, Kern J et al. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J Clin Pathol 2005; 58: 1180-4.
10. Lass-Flörl C, Resch G, Nachbaur D et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45: e101-4.
11. de Hoog GS, Guarro J, Gene J et al. Atlas of Clinical Fungi. Utrecht/Reus: Centraalbureau voor Schimmelcultures/Universitat Rovira i Virgili, 2000.
12. Dannaoui E, Schwarz P, Slany M et al. Molecular detection and identification of Zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis-a collaborative ESCMID Fungal Infection Study Group (EFISG) evaluation. J Clin Microbiol 2010; 48: 2043-6.
13. Hayden RT, Isotalo PA, Parrett T et al. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol 2003; 12:21-6.
14. Lau A, Chen S, Sorrell T et al. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J Clin Microbiol 2007; 45: 380-5.
15. Cendejas-Bueno E, Gomez-Lopez A, Mellado E et al. Identification of pathogenic rare yeast species in clinical samples: comparison between phenotypical and molecular methods. J Clin Microbiol 2010; 48: 1895-9.
16. Balajee SA, Kano R, Baddley JW et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47: 3138-41.
17. Balajee SA, Borman AM, Brandt ME et al. Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol 2009; 47: 877-84.
18. Guarro J, Gene J, Stchigel AM. Developments in fungal taxonomy. Clin Microbiol Rev 1999; 12: 454-500.
19. Gotway MB, Dawn SK, Caoili EM et al. The radiologic spectrum of pulmonary Aspergillus infections. J Comput Assist Tomogr 2002; 26: 159-73.
20. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
21. de Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
22. Prevost E, Newell R. Commercial cryptococcal latex kit: clinical evaluation in a medical center hospital. J Clin Microbiol 1978; 8: 529-33.
23. Cordonnier C, Botterel F, Ben Amor R et al. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect 2009; 15:81-6.
24. Maertens J, Theunissen K, Verbeken E et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126: 852-60.
25. Maertens JA, Klont R, Masson C et al. Optimization of the cut-off value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44: 1329-36.
26. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417-27.
27. Leeflang MM, Debets-Ossenkopp YJ, Visser CE et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008; 8: CD007394.
28. Castagnola E, Furfaro E, Caviglia I et al. Performance of the galactomannan antigen detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing haemopoietic stem cell transplantation. Clin Microbiol Infect 2010; 16: 1197-203.
29. Koo S, Bryar JM, Baden LR et al. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010; 48: 1255-60.
30. Maertens J, Buve K, Theunissen K et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2009; 115: 355-62.
31. Miceli MH, Grazziutti ML, Woods G et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46: 1412-22.
32. Clancy CJ, Jaber RA, Leather HL et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45: 1759-65.
33. Husain S, Paterson DL, Studer SM et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83:1330-6.
34. Meersseman W, Lagrou K, Maertens J et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177: 27-34.
35. Bergeron A, Belle A, Sulahian A et al. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 2010; 137: 410-5.
36. Maertens J, Maertens V, Theunissen K et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009; 49: 1688-93.
37. Viscoli C, Machetti M, Gazzola P et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002; 40: 1496-9.
38. Marr KA, Laverdiere M, Gugel A et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-9.
39. Hachem RY, Kontoyiannis DP, Chemaly RF et al. Utility of galactomannan enzyme immunoassay and (1,3)--D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. JClinMicrobiol2009; 47:129-33.
40. Viscoli C, Machetti M, Cappellano P et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-6.
41. Mennink-Kersten MA, Klont RR, Warris A et al. Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection. Lancet 2004; 363: 325-7.
42. Aquino VR, Goldani LZ, Pasqualotto AC. Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. Mycopathologia 2007; 163: 191-202.
43. Racil Z, Kocmanova I, Lengerova M et al. Intravenous Plasma-Lyte as a major cause of false-positive results of platelia Aspergillus test for galactomannan detection in serum. J Clin Microbiol 2007; 45: 3141-2.
44. Third European Conference on Infections in Leukaemia (ECIL3). Antifungal therapy in leukemia patients. 2009 update of the ECIL1 and ECIL2 guidelines. http://www.ichs.org/Resources/Documents/ECIL%203%20Antifungal%20therapy% 20Update%202009.pdf (21 July 2010, date last accessed).
45. Koo S, Bryar JM, Page JH et al. Diagnostic performance of the (1→3)-β-D-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49: 1650-9.
46. Obayashi T, Negishi K, Suzuki T et al. Reappraisal of the serum (1→3)-β-D-glucan assay for the diagnosis of invasive fungal infections-a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46: 1864-70.
47. Desmet S, Van Wijngaerden E, Maertens J et al. Serum (1→3)-β-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 2009; 47: 3871-4.
48. Marty FM, Koo S, Bryar J et al. (1→3)-β-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007; 147:70-2.
49. Odabasi Z, Mattiuzzi G, Estey E et al. β-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
50. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1→3)-β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-9.
51. Pickering JW, Sant HW, Bowles CAP et al. Evaluation of a (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957-62.
52. Racil Z, Kocmanova I, Lengerova M et al. Difficulties in using (1→3)-β-D-glucan as the screening test for the early diagnosis of invasive fungal diseases in patients with hematological malignancies-high frequency of false positive results and their analysis. J Med Microbiol 2010; 59: 1016-22.
53. Senn L, Robinson JO, Schmidt S et al. (1→3)-β-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46: 878-85.
54. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 2006; 42: 487-9.
55. Khot PD, Ko DL, Hackman RC et al. Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC Infect Dis 2008; 8: 73.
56. Mengoli C, Cruciani M, Barnes RA et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 89-96.
57. White PL, Bretagne S, Klingspor L et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010; 48: 1231-40.
58. Suarez F, Lortholary O, Buland S et al. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol 2008; 46: 3772-7.
59. Frealle E, Decrucq K, Botterel F et al. Diagnosis of invasive aspergillosis using bronchoalveolar lavage in haematology patients: influence of bronchoalveolar lavage human DNA content on real-time PCR performance. Eur J Clin Microbiol Infect Dis 2009; 28: 223-32.
60. Hummel M, Spiess B, Roder J et al. Detection of Aspergillus DNA by a nested PCR assay is able to improve the diagnosis of invasive aspergillosis in paediatric patients. J Med Microbiol 2009; 58: 1291-7.
61. Klingspor L, Loeffler J. Aspergillus PCR formidable challenges and progress. Med Mycol 2009; 47 Suppl 1: S241-7.
62. Barnes RA, White PL, Bygrave C et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 2009; 62:64-9.
63. Cuenca-Estrella M, Meije Y, Diaz-Pedroche C et al. Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropenia. J Clin Microbiol 2009; 47: 379-84.
64. Hebart H, Klingspor L, Klingebiel T et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 2009; 43: 553-61.
65. Armenian SH, Nash KA, Kapoor N et al. Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. J Pediatr Hematol Oncol 2009; 31: 920-6.
66. Blennow O, Remberger M, Klingspor L et al. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant 2010; doi:10.1038/bmt.2010.38.
67. Ahmad S, Khan ZU, Theyyathel AM. Development of a nested PCR assay for the detection of Fusarium solani DNA and its evaluation in the diagnosis of invasive fusariosis using an experimental mouse model. Mycoses 2010; 53:40-7.
68. Buitrago MJ, Merino P, Puente S et al. Utility of real-time PCR for the detection of Paracoccidioides brasiliensis DNA in the diagnosis of imported paracoccidioidomycosis. Med Mycol 2009; 47: 879-82.
69. Castelli MV, Buitrago MJ, Bernal-Martinez L et al. Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J Clin Microbiol 2008; 46: 3412-6.
70. Hata DJ, Buckwalter SP, Pritt BS et al. Real-time PCR method for detection of zygomycetes. J Clin Microbiol 2008; 46: 2353-8.
71. Kasai M, Harrington SM, Francesconi A et al. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol 2008; 46: 3690-702.
72. Rickerts V, Bialek R, Tintelnot K et al. Rapid PCR-based diagnosis of disseminated histoplasmosis in an AIDS patient. Eur J Clin Microbiol Infect Dis 2002; 21: 821-3.
73. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi-Second Edition: Approved Standard M38-A2. CLSI, Wayne, PA, USA, 2008.
74. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
75. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC et al. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds-Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). Clin Microbiol Infect 2008; 14: 982-4.
76. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F et al. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008; 14: 398-405.
77. Cuesta I, Bielza C, Cuenca-Estrella M et al. Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI), and its comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob Agents Chemother 2010; 54: 1541-6.
78. Rex JH, Pfaller MA, Walsh TJ et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-58.
79. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-47.
80. Rodriguez-Tudela JL, Arendrup MC, Cuenca-Estrella M et al. EUCAST breakpoints for antifungals. Drug News Perspect 2010; 23:93-7.
81. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008; 52: 2468-72.
82. Verweij PE, Howard SJ, Melchers WJ et al. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009; 12: 141-7.
83. Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N et al. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J Clin Microbiol 2007; 45: 1811-20.
84. Guinea J, Pelaez T, Recio S et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52: 1396-400.
85. Martos AI, Romero A, Gonzalez MT et al. Evaluation of the Etest method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins. Med Mycol 2010; 48: 858-61.
86. Messer SA, Diekema DJ, Hollis RJ et al. Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi. J Clin Microbiol 2007; 45: 1322-4.
87. Cuenca-Estrella M, Rodriguez-Tudela JL. The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro. Expert Rev Anti Infect Ther 2010; 8: 267-76.
88. Lass-Flörl C, Perkhofer S, Mayr A. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses 2010; 53: 1-11.
89. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24-34.
90. Bruggemann RJ, Alffenaar JW, Blijlevens NM et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.
91. Hope WW, Billaud EM, Lestner J et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21: 580-6.
92. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56 Suppl 1: i17-22.
93. Bruggemann RJ, Donnelly JP, Aarnoutse RE et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008; 30: 403-11.
94. Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
95. Trifilio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532-5.
96. Lebeaux D, Lanternier F, Elie C et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009; 53: 5224-9.
97. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008; 42: 1429-38.